Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

By Michael Gibney • Feb. 20, 2025

CRISPR’s cardio catch-all drives a biotech’s broad potential

Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.

By Kelly Bilodeau • Feb. 18, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.

By Michael Gibney • Feb. 13, 2025

In the crowded cardio space, it’s David vs. Goliath for small biotechs

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

By Alexandra Pecci • Feb. 11, 2025

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

By Amy Baxter • Feb. 10, 2025

As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D

With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.

By Alexandra Pecci • Feb. 5, 2025

Drugmakers prep for bird flu outbreak, despite continued low risk

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

By Kelly Bilodeau • Feb. 3, 2025

Pharma’s forecast for 2025: Sowing seeds of a rebound

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

By Meagan Parrish • Jan. 31, 2025

A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

By Amy Baxter • Updated Feb. 4, 2025

Executive hiring changes reflect a broader biotech comeback

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

By Alexandra Pecci • Jan. 29, 2025

Natural killer cells, a rising alternative to CAR-T cell therapy

These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.

By Kelly Bilodeau • Jan. 27, 2025

Gene therapies have been uneven for DMD — but these companies hope to turn the tide

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.

By Meagan Parrish • Jan. 24, 2025

J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?

Anti-tau candidates haven’t crossed the regulatory threshold like their anti-amyloid counterparts, but J&J’s clinical efforts could lead in the right direction.

By Michael Gibney • Jan. 23, 2025

After an obesity stumble, BioAge reconnects with its longevity pipeline

The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.

By Alexandra Pecci • Jan. 22, 2025

‘The bar has risen’: China’s biotech gains push US companies to adapt

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder.

By Ben Fidler • Jan. 17, 2025

Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking

There’s more to pharma's regulatory story in 2025 than just the IRA.

By Meagan Parrish • Jan. 17, 2025

By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years

The J.P. Morgan Healthcare Conference has been a focal point for M&A year after year, and after a quiet period, the deals are back on the table.

By Michael Gibney • Jan. 16, 2025

Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?

A series of uncertainties that kept dealmaking to a minimum last year could be reversing as pharma reloads pipelines ahead of the patent cliff explosion.

By Michael Gibney • Jan. 14, 2025

PharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials

Coming changes that could impact pharma from drug development to launch.

By Meagan Parrish • Jan. 10, 2025

After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win

Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.

By Michael Gibney • Jan. 9, 2025

3 trial readouts that could shake up the obesity market this year

A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.

By Amy Baxter • Jan. 8, 2025

PharmaVoice’s Crystal Ball: The industry’s AI future

How AI will further transform the business of drug discovery and development in 2025.

By Meagan Parrish • Jan. 7, 2025

4 closely watched FDA approval dates in 2025 from J&J, Novo and more

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.

By Alexandra Pecci • Jan. 6, 2025

4 companies to watch in the accelerating gene editing race

A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.

By Kelly Bilodeau • Jan. 2, 2025

10 of our most read articles of 2024

The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.

By Meagan Parrish • Dec. 20, 2024